Cefepime (BMY-28142): Broad-Spectrum Cephalosporin for CNS Infection Research

Executive Summary: Cefepime (BMY-28142) is a fourth-generation cephalosporin antibiotic with activity against a wide range of Gram-positive and Gram-negative aerobic bacteria [APExBIO Product]. Its capacity to cross the blood-brain barrier enables the study of central nervous system (CNS) infections in preclinical models [CefazolinAPI Review]. Cefepime functions by inhibiting bacterial cell wall synthesis, resulting in cell lysis. Resistance rates in carbapenemase-encoding gene (CEG)-positive Enterobacter cloacae isolates are significantly higher compared to CEG-negative strains (Chen et al. 2025). Research applications must account for potential neurotoxicity and strict storage guidelines at –20°C for stability. Solutions should be freshly prepared and not stored long-term [APExBIO].

Biological Rationale

Cefepime (BMY-28142) is classified as a broad-spectrum, fourth-generation cephalosporin antibiotic. It is structurally designed to resist hydrolysis by most beta-lactamases, including AmpC and extended-spectrum beta-lactamases (ESBLs) [APExBIO]. The compound’s ability to penetrate the blood-brain barrier differentiates it from many other cephalosporins and supports its use in CNS infection research [Gentamycin-Sulfate Article]. Its molecular formula is C19H24N6O5S2 and the precise molecular weight is 480.56 g/mol, ensuring reproducibility in dosing and pharmacokinetic studies. Cefepime is only intended for research use, not for diagnostic or medical purposes [APExBIO].

Mechanism of Action of Cefepime (BMY-28142)

Cefepime exerts its antibacterial effects by binding to penicillin-binding proteins (PBPs) on the bacterial cell wall. This action inhibits the final transpeptidation step of peptidoglycan synthesis, leading to cell wall instability, lysis, and death [ClothiapineAPIs Article]. Its beta-lactam ring is resistant to many hydrolytic enzymes produced by resistant bacteria. Cefepime’s structure allows enhanced penetration through outer membranes of Gram-negative bacteria and rapid affinity for PBPs, contributing to its broad spectrum of activity. Notably, it is effective even against many strains expressing ESBLs and AmpC beta-lactamases, which are common in multidrug-resistant bacterial infections (Chen et al. 2025).

Evidence & Benchmarks

• In a study of 54 carbapenem-resistant Enterobacter cloacae isolates, 85.19% were positive for carbapenemase-encoding genes (CEGs), with the blaNDM-1 gene predominant (Chen et al. 2025, doi.org/10.1186/s12866-025-04300-0).
• The minimum inhibitory concentration (MIC) for cefepime against CEG-positive Enterobacter cloacae strains was significantly higher than for CEG-negative strains (P<0.05), supporting its use in resistance benchmarking (Chen et al. 2025, doi.org/10.1186/s12866-025-04300-0).
• Cefepime consistently crosses the blood-brain barrier in animal models, enabling CNS infection studies (NortriptylinePharma Review, nortriptylinepharma.com).
• Storage at –20°C preserves solid cefepime stability for up to 12 months; solutions should be freshly prepared (APExBIO).
• Neurotoxicity has been observed at supratherapeutic concentrations, especially in models with impaired renal clearance (Gentamycin-Sulfate Article, gentamycin-sulfate.com).

Applications, Limits & Misconceptions

Cefepime (BMY-28142) is widely used in the following research applications:

• Central nervous system infection models, owing to strong blood-brain barrier permeability [CefazolinAPI Review].
• Studies of Gram-positive and Gram-negative bacterial infections, including carbapenem-resistant Enterobacter cloacae (Chen et al. 2025).
• Antibiotic resistance benchmarking and transmission dynamics research (Chen et al. 2025).
• Pharmacokinetics and neurotoxicity studies, particularly in renal impairment models [Gentamycin-Sulfate Advanced Insights].

This article extends the guidance provided in NortriptylinePharma's guide by providing detailed resistance benchmarks and highlighting storage pitfalls.

Common Pitfalls or Misconceptions

• Not effective against all carbapenemase-producing organisms: CEG-positive strains may exhibit high-level cefepime resistance, especially with plasmid-borne blaNDM-1 genes (Chen et al. 2025).
• Inappropriate for long-term solution storage: Cefepime solutions degrade rapidly; always prepare fresh aliquots (APExBIO).
• Neurotoxicity risk underestimated: Even at moderate concentrations, neurotoxic effects are possible in renal impairment models [Gentamycin-Sulfate].
• Not for clinical or diagnostic use: Research-use only; not validated for therapeutic application (APExBIO).
• Confusion with earlier cephalosporins: Cefepime’s spectrum and blood-brain barrier penetration are distinct from earlier generations [ClothiapineAPIs].

Workflow Integration & Parameters

• Formulation: Provided as a solid; molecular weight 480.56 g/mol; chemical formula C19H24N6O5S2 (APExBIO).
• Storage: Store at –20°C. Avoid repeated freeze-thaw cycles. Solutions must be used within hours of preparation.
• Dosing: Reference published MIC and in vitro PK/PD models; titrate based on target organism and resistance profile.
• Controls: Include Gram-positive and Gram-negative standards for benchmarking activity and resistance.
• Safety: Exercise caution for neurotoxicity, especially in CNS and renal impairment studies.

The Cefepime (BMY-28142) BA1013 kit from APExBIO is optimized for these workflows. This article clarifies benchmarking protocols beyond those in CefazolinAPI's review by including recent resistance and stability data.

Conclusion & Outlook

Cefepime (BMY-28142) remains a critical research antibiotic for CNS infection and antibiotic resistance models. Its broad-spectrum activity and blood-brain barrier penetration are well-characterized, but resistance is increasing, especially in CEG-positive Enterobacter cloacae. Strict adherence to storage, handling, and dosing protocols is essential for reproducible results. Future research will benefit from integrating real-time resistance monitoring and exploring novel derivatives with reduced neurotoxicity.